Survival of patients with oropharyngeal squamous cell carcinomas (OPSCC) in relation to TNM 8 – Risk of incorrect downstaging of HPV-mediated non-tonsillar, non-base of tongue carcinomas
TNM-8 staging separates oropharyngeal squamous cell carcinomas (OPSCC) into human papillomavirus (HPV)-mediated and -unrelated OPSCC based on p16INK4a overexpression (p16+), as surrogate marker for HPV. However, OPSCC is histologically and clinically heterogenous including tonsillar and base of tongue squamous cell carcinomas (TSCC and BOTSCC respectively), and carcinomas of soft palate and walls (otherOPSCC). The significance of HPV is established in TSCC/BOTSCC, while its role in otherOPSCC is unclear, which is not considered in TNM-8. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 17, 2020 Category: Cancer & Oncology Authors: Linda Marklund, Stefan Holzhauser, Caroline de Flon, Mark Zupancic, David Landin, Aeneas Kolev, Linnea Haeggblom, Eva Munck-Wikland, Lalle Hammarstedt-Nordenvall, Tina Dalianis, Anders N äsman Tags: Original Research Source Type: research

Malignant peritoneal cytology in endometrial cancer
We read with interest the paper from Matsuo et  al. [1] The authors performed a retrospective cohort study on early stage endometrial cancer staging, using data from the Surveillance, Epidemiology, and End Results (SEER) Program, from 2010 to 2016. They observed that malignant peritoneal cytology is associated with worse survival outcomes in wo men with stage I endometrioid endometrial cancer, and the major impact was observed in intermediate-high risk subgroup [1]. The last 2009 FIGO (International Federation of Obstetrics and Gynecology) staging system revised the previous system (FIGO 1988) modifying the criteria t...
Source: European Journal of Cancer - September 10, 2020 Category: Cancer & Oncology Authors: Ciro Pinelli, Giorgio Bogani, Jvan Casarin, Francesco Raspagliesi, Fabio Ghezzi Tags: Letter to the Editor Source Type: research

Immunological features of coronavirus disease 2019 in patients with cancer
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has caused a major pandemic. Patients with cancer are at higher risk of severe COVID-19. We aimed to describe and compare the immunological features of cancer patients hospitalized for COVID-19 or other concomitant, cancer-related illness. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 7, 2020 Category: Cancer & Oncology Authors: Marion Thibaudin, Jean-David Fumet, Marjorie Bon, L éa Hampe, Emeric Limagne, Francois Ghiringhelli Tags: Original Research Source Type: research

Risk of death of cancer patients presenting with severe symptoms of infection, with or without documented COVID-19
Funding (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 6, 2020 Category: Cancer & Oncology Authors: Souad Assaad, Christine Fuhrmann, Virginie Avrillon, Isabelle Ray-Coquard, Jean-Yves Blay Tags: Author ’s reply Source Type: research

Comment on: Developing a risk assessment score for patients with cancer during the coronavirus disease 2019 pandemic
We have read with interest the article “Developing a risk assessment score for patients with cancer during the coronavirus disease 2019 pandemic” [1]. The authors propose a score to evaluate the risk of patients with cancer of developing complications if infected by COVID-19 and provide patient management recommendations according to the resulting risk stratification. The idea is interesting and could potentially benefit patients. However, we have substantial concerns regarding the methodology used to produce this score and its applicability. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 6, 2020 Category: Cancer & Oncology Authors: Francisco Bautista, Alba Rubio, Jaime Verd ú, Anouk Neven, Teresa de Rojas Tags: Letter to the Editor Source Type: research

Response to letter commenting on ʻindications for hyperthermic intraperitoneal chemotherapy (Hipec) with cytoreductive surgery: a systematic reviewʼ
We thank M. Soucisse et  al. for their informed reply and perspective related to the treatment of rare peritoneal surface malignancies, such as pseudomyxoma peritonei and mesothelioma. While we appreciate that level one evidence may be difficult or impossible to generate for rare cancers, the Program in Evidence Based Car e has defined a rigorously developed process to systematically search for, identify and analyse primary study evidence. The process is not meant to provide a complete summary of all the available evidence but to identify studies that are relevant for the formulation of recommendations. (Source: Europ...
Source: European Journal of Cancer - September 5, 2020 Category: Cancer & Oncology Authors: Rebecca Auer, Duvaraga Sivajohanathan, Jim Biagi, James Conner, Erin Kennedy, Taymaa May Tags: Letter to the Editor Source Type: research

Mortality in patients with cancer and COVID-19: A systematic review and pooled analysis of 52 studies
Patients with COVID-19 who have underlying malignancy have a higher mortality rate compared with those without cancer, although the magnitude of such excess risk is not clearly defined. We performed a systematic review and pooled analysis to provide precise estimates of the mortality rate among patients with both cancer and COVID-19. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 2, 2020 Category: Cancer & Oncology Authors: Kamal S. Saini, Marco Tagliamento, Matteo Lambertini, Richard McNally, Marco Romano, Manuela Leone, Giuseppe Curigliano, Evandro de Azambuja Tags: Original Research Source Type: research

Letter responds to comment on “intention-to-treat analysis in precision oncology: A cautious interpretation”
We thank Drs. Garg, Kaul, and Choudhary for their thoughtful comments. We agree that intention-to-treat (ITT)  analysis is best for randomized randomised controlled trials of unselected patients and that per protocol (PP) analysis is best for precision medicine studies wherein biomarker-based patient selection occurs. The latter includes only patients with the relevant biomarker in the analysis [1]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 21, 2020 Category: Cancer & Oncology Authors: Jason Sicklick, Shumei Kato, Razelle Kurzrock Tags: Letter to the Editor Source Type: research

Intention-to-treat analysis in precision oncology: A cautious interpretation
Randomised clinical trials (RCTs) are the best available study designs to confirm the effectiveness of a new intervention. The process of randomisation produces two prognostically equal groups which are similar in all aspects except that one group receives the new intervention whereas the other does not. However, these two groups may not remain similar in due course after randomisation if the participants leave their assigned groups because of varied reasons – high cost, more side effects, inconvenience, alternative options, etc. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 20, 2020 Category: Cancer & Oncology Authors: Pankaj K. Garg, Pallvi Kaul, Deepti Choudhary Tags: Letter to the Editor Source Type: research

Ramucirumab and durvalumab for previously treated, advanced non –small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
Emerging evidence supports combining immune checkpoint inhibitors (ICIs) with conventional or targeted therapies to enhance ICI antitumour activity and broaden the spectrum of patients who respond to ICIs. Here, we present the safety and preliminary efficacy of ramucirumab, an anti-VEGFR2 IgG1, plus durvalumab, an anti –PD-L1 IgG1, in previously treated patients with advanced non–small-cell lung cancer (NSCLC), gastric/gastro-oesophageal junction adenocarcinoma (gastric/GEJ), or hepatocellular carcinoma (HCC). (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 19, 2020 Category: Cancer & Oncology Authors: Yung-Jue Bang, Talia Golan, Laetitia Dahan, Siqing Fu, Victor Moreno, Keunchil Park, Ravit Geva, Filippo De Braud, Zev A. Wainberg, Martin Reck, Laura Goff, Naomi Laing, Gu Mi, Joana M. Oliveira, Heather Wasserstrom, Chia-Chi Lin Tags: Original Research Source Type: research

Chemokine biology on immune checkpoint –targeted therapies
The use of antagonistic immune checkpoint –targeted monoclonal antibodies has profoundly modified the standard of care and significantly increased the survival for many cancers. However, many patients still do not respond to those treatments. Biomarkers predictive for efficacy or failure of such immunotherapies would allow developing trea tment stratification strategies which could further increase the survival rates of patients with cancer. Chemokines are a subset of the immune cell messenger molecules known as cytokines. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 18, 2020 Category: Cancer & Oncology Authors: Diane Letourneur, Fran çois-Xavier Danlos, Aurélien Marabelle Tags: Review Source Type: research

Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial
Molecular biomarkers and primary tumour sidedness guide treatment decisions in metastatic colorectal cancer. Comprehensive molecular profiling aims to identify targetable alterations and measure tumour mutational burden (TMB) to enable precision oncology. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 15, 2020 Category: Cancer & Oncology Authors: Arndt Stahler, Sebastian Stintzing, Jobst C. von Einem, Christoph B. Westphalen, Kathrin Heinrich, Nicole Kr ämer, Marlies Michl, Dominik P. Modest, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Tobias Heintges, Christoph Kahl, Frank Ku Tags: Original Research Source Type: research

Clinically significant bleeding with immune checkpoint inhibitors: A retrospective cohort study
Immune checkpoint inhibitors (ICIs) have changed the clinical outcomes of many malignancies. ICIs have been approved for the treatment of multiple malignancies including melanoma, non –small-cell lung cancer (NSCLC) and renal cell cancer. ICIs target programmed cell death receptor-1 or ligand-1 (PD-1/PD-L1) and lymphocyte-associated protein 4 to activate the immune system against cancer cells [1]. Haematological immune-related adverse events (hem-irAEs) are rare compared with the involvement of other organ systems and include immune thrombocytopenia (ITP), acute haemolytic anaemia (HA), aplastic anaemia and haem...
Source: European Journal of Cancer - August 15, 2020 Category: Cancer & Oncology Authors: Tariq Kewan, Fahrettin Covut, Ramsha Ahmed, Abdo Haddad, Hamed Daw Tags: Letter to the Editor Source Type: research

Response to the letter commenting on ʻEffect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic reviewʼ
We thank Dr. Dugu é and colleagues for their response to our systematic review [1] on the effect of organised cervical screening on cervical cancer mortality in Europe. Dugué and colleagues emphasise how difficult it is to estimate the effect of cervical cancer screening, because no unselected unscreened group is a vailable and women who do not participate in screening often have a higher a priori risk of cervical cancer mortality. This was highlighted in their study [2], which we included in our review, that showed that self-selection bias influences estimates of cervical cancer screening effects. (Source: E...
Source: European Journal of Cancer - August 15, 2020 Category: Cancer & Oncology Authors: Erik E.L. Jansen, Nadine Zielonke, Andrea Gini, Ahti Anttila, Nereo Segnan, Zolt án Vokó, Urška Ivanuš, Martin McKee, Harry J. de Koning, Inge M.C.M. de Kok Tags: Letter to the Editor Source Type: research

Letter comments on ʻIndications for hyperthermic intraperitoneal chemotherapy (Hipec) with cytoreductive surgery: a systematic reviewʼ
We read and analysed with interest the article from Auer RC et  al. [1]. We would like to offer a different perspective on the conclusions relating to the treatment of peritoneal surface malignancy originating from rare tumours such as mesothelioma and pseudomyxoma peritonei (PMP). (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 15, 2020 Category: Cancer & Oncology Authors: Mikael L. Soucisse, Micheal Flood, Lucas Sideris, Pierre Dub é, Alexander Heriot Tags: Letter to the Editor Source Type: research

Palliative care delivery according to age in 12,000 women with metastatic breast cancer: Analysis in the multicentre ESME-MBC cohort 2008 –2016
This study aimed to assess the cumulative incidence function (CIF) of IPC delivery, as well as the influence of age. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 14, 2020 Category: Cancer & Oncology Authors: Matthieu Frasca, Camille Sabathe, Suzette Delaloge, Angeline Galvin, Anne Patsouris, Christelle Levy, Marie A. Mouret-Reynier, Isabelle Desmoulins, Laurence Vanlemmens, Thomas Bachelot, Anthony Goncalves, Virginie Perotin, Lionel Uwer, Jean S. Frenel, Jea Tags: Original Research Source Type: research

Lymphoblastic predominance of blastic phase in children with chronic myeloid leukaemia treated with imatinib: A report from the I-CML-Ped Study
Chronic myeloid leukaemia (CML) is a rare disease in children. The frequency and outcome of children evolving to accelerated phase (AP) or blastic phase (BP) under treatment with imatinib is unknown. The aim of the current study is to assess the incidence of progression from CML in chronic phase with imatinib frontline in a paediatric setting and describe the management and outcome of these patients. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 13, 2020 Category: Cancer & Oncology Authors: Deborah Meyran, Arnaud Petit, Joelle Guilhot, Meinolf Suttorp, Petr Sedlacek, Eveline De Bont, Chi Kong Li, Krzysztof Kalwak, Birgitte Lausen, Srdjana Culic, Barbara de Moerloose, Andrea Biondi, Fr édéric Millot Tags: Original Research Source Type: research

Trends in incidence, diagnosis, treatment and survival of hepatocellular carcinoma in a low-incidence country: Data from the Netherlands in the period 2009 –2016
Evaluation of the trends in incidence, diagnostics, treatment and survival of patients with hepatocellular carcinoma (HCC) in the Netherlands. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 13, 2020 Category: Cancer & Oncology Authors: Margot T.M. Reinders, Suzanne van Meer, Mark C. Burgmans, Koert P. de Jong, Heinz-Josef Kl ümpen, Robert A. de Man, D. (Sandjai) Ramsoekh, Dave Sprengers, Eric T.T.L. Tjwa, Judith de Vos-Geelen, Karel J. van Erpecum, Lydia G.M. van der Geest, Dutch Hepat Tags: Original Research Source Type: research

A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies
Talazoparib combined with irinotecan and temozolomide demonstrated efficacy in a murine Ewing sarcoma model. Based on these data, we conducted a phase I trial of talazoparib and irinotecan with/without temozolomide in paediatric patients with recurrent/refractory solid malignancies. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 11, 2020 Category: Cancer & Oncology Authors: Sara M. Federico, Alberto S. Pappo, Natasha Sahr, April Sykes, Olivia Campagne, Clinton F. Stewart, Michael R. Clay, Armita Bahrami, Mary B. McCarville, Sue C. Kaste, Victor M. Santana, Sara Helmig, Jessica Gartrell, Anang Shelat, Rachel C. Brennan, Dana Tags: Original Research Source Type: research

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial
The clinical utility of the 70-gene signature (MammaPrint ®) to guide chemotherapy use in T1-3N0-1M0 breast cancer was demonstrated in the Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy (MINDACT) study. One thousand four ninety seven of 3356 (46.2%) enrolled patients with high clinical risk (in accordance with th e modified Adjuvant! Online clinical-pathological assessment) had a low-risk 70-gene signature. Using patient-level data from the MINDACT trial, the cost-effectiveness of using the 70-gene signature to guide adjuvant chemotherapy selection for clinical high risk, estr...
Source: European Journal of Cancer - August 11, 2020 Category: Cancer & Oncology Authors: Valesca P. Ret èl, Danalyn Byng, Sabine C. Linn, Katarzyna Jóźwiak, Hendrik Koffijberg, Emiel J. Rutgers, Fatima Cardoso, Martine J. Piccart, Coralie Poncet, Laura J. van't Veer, Wim H. van Harten Tags: Original Research Source Type: research

Favourable outcome of COVID-19 in an ALK-positive NSCLC patient receiving Alectinib
Since February 21, 2020, when the first Italian patient was admitted to the hospital due to severe coronavirus disease 2019 (COVID-19) and found positive to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this infection has spread through Italy, quickly becoming the largest COVID-19 outbreak outside Asia1. In March the 12th World Health Organization (WHO) declared COVID-19 pandemic, placing WHO European Region at the center of pandemic. Elderly people and those with pre-existing health conditions are most at risk of life-threatening complications2. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 11, 2020 Category: Cancer & Oncology Authors: Michele Montrone, Annamaria Catino, Vincenzo Ostilio Palmieri, Vito Longo, Domenico Galetta Tags: Letter to the Editor Source Type: research

High mortality of cancer patients in times of SARS-Cov-2: do not generalize!
Being heavily involved in the treatment of cancer patients in times of the SARS-Cov-2 pandemic,1,2 we read with great interest the papers of Assaad et al3 and Yarza et al4 in the Eur J Cancer. Assaad et al performed an exciting retrospective analysis of 302 cancer patients presenting between March 1st to April 15th in the Comprehensive Cancer Center of Lyon with a suspicion of COVID-19.3 In 55 (18.2%) them the Cobas real time polymerase chain reaction (PCR, Roche, Neuilly) was positive for SARS-CoV-2, and in 247 (81.8%) it proved to be negative. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 10, 2020 Category: Cancer & Oncology Authors: Peter A. van Dam, Manon Huizing, Kostantinos Papadimitriou, Hans Prenen, Marc Peeters Tags: Letter to the Editor Source Type: research

Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies
Targeted neurotrophic tropomyosin receptor kinase (TRK) inhibitors offer a highly specific therapeutic option for patients with infantile fibrosarcoma (IFS) carrying the NTRK gene translocation. International recommendations are needed to define the role of TRK inhibitors (TRKI) for infants with IFS. We analysed retrospective data for all published patients with IFS in the European Paediatric Soft tissue sarcoma Study Group and Cooperative Weichteilsarkomstudiengruppe (CWS) experience and developed a consensus strategy with the Children's Oncology Group. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 9, 2020 Category: Cancer & Oncology Authors: Daniel Orbach, Monika Sparber-Sauer, Theodore W. Laetsch, Veronique Minard-Colin, Stefan S. Bielack, Michela Casanova, Nadege Corradini, Ewa Koscielniak, Monika Scheer, Simone Hettmer, Gianni Bisogno, Douglas S. Hawkins, Andrea Ferrari Tags: Current Perspective Source Type: research

SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment
Sentinel lymph node (SLN) biopsy remains crucial for melanoma staging. The European Organisation for Research and Treatment of Cancer  Melanoma Group recommends performing immunohistochemical stainings for reproducible identification of melanoma metastases. S100 protein (pS100) is a commonly used melanocytic antigen because of its high sensitivity in spite of relatively low specificity. SRY-related HMG-box 10 protein (SOX10) is a transcription factor characterising neural crest-derived cells. It is uniformly expressed mostly in the nuclei of melanocytes, neural, and myoepithelial cells. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 8, 2020 Category: Cancer & Oncology Authors: Anna Szumera-Cie ćkiewicz, Francesca Bosisio, Paweł Teterycz, Asier Antoranz, Francesco Delogu, Senada Koljenović, Bart A. van de Wiel, Willeke Blokx, Léon C. van Kempen, Piotr Rutkowski, Alexander Christopher van Akkooi, Martin Cook, Daniela Massi, E Tags: Original Research Source Type: research

Updated EORTC QLQ-C30 general population norm data for Germany
This article presents updated general population norm data for the EORTC QLQ-C30 for Germ any. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 7, 2020 Category: Cancer & Oncology Authors: Sandra Nolte, Annika Waldmann, Gregor Liegl, Morten Aa Petersen, Mogens Groenvold, Matthias Rose, EORTC Quality of Life Group Tags: Original Research Source Type: research

Benefit of adjuvant chemotherapy in high-risk colon cancer: A 17-year population-based analysis of 6131 patients with Union for International Cancer Control stage II T4N0M0 colon cancer
The benefit of adjuvant chemotherapy in Union for International Cancer Control (UICC) stage III colon cancer has been demonstrated in numerous studies. While adjuvant chemotherapy is generally not recommended in stage II patients, its role in high-risk UICC stage II disease (e.g. T4 tumours) remains controversial. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 7, 2020 Category: Cancer & Oncology Authors: Andreas Teufel, Michael Gerken, Alois F ürst, Matthias Ebert, Ina Hohenthanner, Monika Klinkhammer-Schalke Tags: Original Research Source Type: research

Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors
Recent changes in the adjuvant treatment of melanoma have raised interest in confirming relapse-free survival (RFS) as a surrogate for overall survival (OS). (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 7, 2020 Category: Cancer & Oncology Authors: Elisabeth Coart, Stefan Suciu, Pierre Squifflet, Everardo D. Saad, Andriy Moshyk, Gaetan de Schaetzen, Marc Buyse, Jeffrey S. Weber, Alexander Eggermont, Srividya Kotapati Tags: Original Research Source Type: research

Fibrolamellar carcinoma: Challenging the challenge
Fibrolamellar carcinoma (FLC) is a rare and poorly understood malignancy, which seems to be more prevalent in young patients compared with conventional hepatocellular carcinoma (HCC). Performing prospective clinical trials recruiting patients diagnosed with FLC has proven challenging with scarce data available guiding clinical management. The use of a number of chemotherapy compounds in these patients, including cisplatin, epirubicin, 5-fluorouracil (5-FU) and recombinant interferon α-2B (IFN-α-2B), has been reported in the literature, mainly in the form of case reports. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 5, 2020 Category: Cancer & Oncology Authors: Angela Lamarca, Melissa Frizziero, Alexander Fulton, Mair éad G. McNamara, Rafik Filobbos, Richard A. Hubner, Steve Wardell, Juan W. Valle Tags: Current Perspective Source Type: research

Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands – A nationwide population-based study
Mucosal melanoma (MM) is rare and has a poor prognosis. Since 2011, new effective treatments are available for advanced melanoma. It is unclear whether patients with mucosal melanoma equally benefit from these new treatments compared with patients with cutaneous melanoma (CM). (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 4, 2020 Category: Cancer & Oncology Authors: Michiel C.T. van Zeijl, Florine L. Boer, Mari ëtte I.E. van Poelgeest, Alfons J.M. van den Eertwegh, Michel W.J.M. Wouters, Liesbeth C. de Wreede, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Djura Tags: Original Research Source Type: research

Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysis
The role of surveillance after surgery for stage IA-C grade 2 (G2) or grade 3 (G3) immature teratomas (ITs) is controversial with many guidelines advocating adjuvant chemotherapy. Here, we investigate the safety of surveillance in stage IA-C G1-3 ITs. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 4, 2020 Category: Cancer & Oncology Authors: Alice Bergamini, Naveed Sarwar, Gabriella Ferrandina, Giovanna Scarfone, Dee Short, Xianne Aguiar, Cristina Camnasio, Baljeet Kaur, Philip M. Savage, Gennaro Cormio, Adrian Lim, Sandro Pignata, Giorgia Mangili, Michael J. Seckl Tags: Original Research Source Type: research

Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer
Immune checkpoint inhibitors (ICIs) alone or in combination with chemotherapy (CT) are the current standard of therapy in several cancer types. Patients (pts) with lung cancer display higher response rates to CT when given after ICIs. Although ICIs have failed to demonstrate antitumour activity in microsatellite stable (MSS) metastatic colorectal cancer (mCRC), little is known about CT effect after ICIs. We aimed to assess whether sequential ICIs followed by CT may be an alternative therapeutic approach in a population of pts with mCRC. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 2, 2020 Category: Cancer & Oncology Authors: Patricia Martin-Romano, Samy Ammari, Yolla El-Dakdoukti, Capucine Baldini, Andreea Varga, Perrine Vuagnat, Eric Angevin, Rastislav Bahleda, Anas Gazzah, Stephane Champiat, Jean M. Michot, Sophie Postel-Vinay, Aurelien Marabelle, Jean C. Soria, Valerie Boi Tags: Original Research Source Type: research

Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study)
The XELAVIRI study compared application of fluoropyrimidine (FP) and bevacizumab (Bev) followed by sequential escalation to irinotecan (Iri), FP and Bev (arm A) to upfront combination therapy with FP, Iri and Bev (arm B) in patients with metastatic colorectal cancer (mCRC). To elucidate the impact of age on survival, we evaluated efficacy and early mortality in the underlying trial. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 1, 2020 Category: Cancer & Oncology Authors: Annika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Florian Kaiser, Jens Uhlig, Michael Schenk, Jens Freiberg-Richter, Bettina Peuser, Claudio Denzlinger, Ullrich Graeven, Ingo Schwaner, Arndt Stahler, Kathrin Heinrich, Andrea Tags: Original Research Source Type: research

Xenograft-derived mRNA/miR and protein interaction networks of systemic dissemination in human prostate cancer
Distant metastasis formation is the major clinical problem in prostate cancer (PCa) and the underlying mechanisms remain poorly understood. Our aim was to identify novel molecules that functionally contribute to human PCa systemic dissemination based on unbiased approaches. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 1, 2020 Category: Cancer & Oncology Authors: Tobias Lange, Timur R. Samatov, Vladimir V. Galatenko, Pascal Steffen, Helge von Kriegstein, Tanja Spethmann, Daniel Wicklein, Hanna Maar, Kristine Kupfernagel, Vera Labitzky, Sandra Hanika, Sarah Starzonek, Ann-Kristin Ahlers, Kristoffer Riecken, Ronald Tags: Original Research Source Type: research

First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?
Gemcitabine plus nab-paclitaxel (Gem-Nab) represents a standard first-line treatment for metastatic pancreatic cancer (mPC), but few data are available for elderly patients. We aimed to add evidence about safety and efficacy of Gem-Nab in this population. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 1, 2020 Category: Cancer & Oncology Authors: Caterina Vivaldi, Francesca Salani, Giulia Rovesti, Irene Pecora, Silvia Catanese, Andrea Casadei-Gardini, Valentina Massa, Laura Bernardini, Laura Riggi, Kalliopi Andrikou, Giovanni I. Rapposelli, Vincenzo Formica, Monica Lencioni, Alfredo Falcone, Enric Tags: Original Research Source Type: research

Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial
SLN biopsy can achieve high bilateral SLN detection in patients with tumours of 4  cm or smaller. At experienced centres, all SLN were found in the pelvis, and most were located below the iliac vessel bifurcation. SLN frozen section assessment is an unreliable tool for intraoperative triage because it only detects about half of N1 cases. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 1, 2020 Category: Cancer & Oncology Authors: David Cibula, Roman Kocian, Andrea Plaikner, Jiri Jarkovsky, Jaroslav Klat, Ignacio Zapardiel, Radovan Pilka, Aureli Torne, Borek Sehnal, Marcela Ostojich, Almerinda Petiz, Octavio A. Sanchez, Jiri Presl, Alessandro Buda, Francesco Raspagliesi, Peter Kasc Tags: Original Research Source Type: research

Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03)
There is a lack of large-scale randomised data evaluating the impact of sex and age in patients undergoing chemotherapy followed by potentially curative surgery for oesophagogastric cancer. (Source: European Journal of Cancer)
Source: European Journal of Cancer - July 31, 2020 Category: Cancer & Oncology Authors: Avani Athauda, Matthew Nankivell, Ruth E. Langley, Derek Alderson, William Allum, Heike I. Grabsch, Naureen Starling, Ian Chau, David Cunningham Tags: Original Research Source Type: research

KRAS inhibition in non –small cell lung cancer: Past failures, new findings and upcoming challenges
Despite the high prevalence of Kirsten rat sarcoma (KRAS) mutations in non-small cell lung cancer (NSCLC), for a long time it has been defined as an ‘undruggable target’, with precision medicine not considered as an adequate approach to treat this subgroup of patients. After several years of efforts, preliminary data from early clinical trials have recently demonstrated that direct pharmacological inhibition of KRAS p.G12C mutation is possib le, emerging as an effective targeted treatment for about 10–12% of patients with advanced NSCLC, with potential relevant impact on their long-term survival and quali...
Source: European Journal of Cancer - July 31, 2020 Category: Cancer & Oncology Authors: Francesco Passiglia, Umberto Malapelle, Marzia Del Re, Luisella Righi, Fabio Pagni, Daniela Furlan, Romano Danesi, Giancarlo Troncone, Silvia Novello Tags: Review Source Type: research

A brief report on combination chemotherapy and anti –programmed death (ligand) 1 treatment in small-cell lung cancer: Did we choose the optimal chemotherapy backbone?
Extensive-stage small-cell lung cancer (ES-SCLC) is an aggressive cancer that remains very hard to treat. The life expectancy of a patient diagnosed with this disease has not changed over the past three decades. Recently, three large clinical studies showed a survival benefit by adding an anti –programmed death (ligand) 1 (PD-(L)1 antibody to the current chemotherapy regimen. Although significant and important, the benefit seems less than what has been achieved in patients with non–small-cell lung cancer treated with chemoimmunotherapy. (Source: European Journal of Cancer)
Source: European Journal of Cancer - July 30, 2020 Category: Cancer & Oncology Authors: Joanne M. Mankor, Fenneke Zwierenga, Daphne W. Dumoulin, Jacques J.C. Neefjes, Joachim G.J.V. Aerts Tags: Current Perspective Source Type: research

Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI)
Sentinel lymph node biopsy (SNB) still remains a key procedure to appropriately stage melanoma patients and to select those who are candidate to novel treatments with immunotherapy and targeted therapy in the adjuvant setting. The impact of timing of SNB on disease-free survival (DFS) and overall survival (OS) is still unclear. (Source: European Journal of Cancer)
Source: European Journal of Cancer - July 30, 2020 Category: Cancer & Oncology Authors: Mario Mandal à, Francesca Galli, Roberto Patuzzo, Andrea Maurichi, Simone Mocellin, Carlo R. Rossi, Eliana Rulli, Maria Montesco, Pietro Quaglino, Virginia Caliendo, Vincenzo De Giorgi, Barbara Merelli, Corrado Caracò, Dario Piazzalunga, Alice Labianca, Tags: Original Research Source Type: research

Active surveillance in desmoid-type fibromatosis: A systematic literature review
This study evaluates the results of the active surveillance (AS) approach in adult patients with desmoid-type fibromatosis (DTF) because AS is advocated as a front-line approach for DTF in the European consensus guidelines. (Source: European Journal of Cancer)
Source: European Journal of Cancer - July 29, 2020 Category: Cancer & Oncology Authors: Milea J.M. Timbergen, Anne-Rose W. Schut, Dirk J. Gr ünhagen, Stefan Sleijfer, Cornelis Verhoef Tags: Review Source Type: research

Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management?
The outbreak of the Coronavirus disease (COVID-19) pandemic has deeply challenged healthcare systems and care of patients with cancer. Phase 1 studies are among the most complicated clinical trials  and require thorough patient selection, as well as intensive patient monitoring. In this perspective, we discuss the key factors that should be considered for the conduct of phase 1 trials and management of COVID-19–positive patients with cancer enrolled in such trials. We notably present the ri sks and challenges raised by COVID-19–infected phase 1 patients, in terms of safety, toxicity causality assessment, d...
Source: European Journal of Cancer - July 27, 2020 Category: Cancer & Oncology Authors: Sophie Postel-Vinay, Christophe Massard, Jean-Charles Soria Tags: Current Perspective Source Type: research

COVID-19 outbreak and Phase 1 trials: should we consider a specific patient management?
The outbreak of the COVID-19 pandemic has deeply challenged health care systems and cancer patients care. Phase 1 studies are among the most complicated clinical trials, and require thorough patient selection as well as intensive patient monitoring. In this perspective, we discuss the key factors that should be considered for the conduct of Phase 1 trials and management of COVID-19-positive cancer patients enrolled in such trials. We notably present the risks and challenges raised by COVID-19 infected Phase 1 patients, in terms of safety, toxicity causality assessment, drug efficacy evaluation, and clinical research priori...
Source: European Journal of Cancer - July 27, 2020 Category: Cancer & Oncology Authors: Sophie Postel-Vinay, Christophe Massard, Jean-Charles Soria Tags: Current Perspective Source Type: research

Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas
Diffuse grade II and grade III gliomas are actually classified in accordance with the presence of isocitrate dehydrogenase mutation (IDH-mut) and the deletion of both 1p and 19q chromosome arms (1p/19q codel). The role of tumour grading as independent prognostic factor in these group of tumours remains matter of debate. The aim of this study was to determine if grade is an independent prognostic factor and not somehow associated to IDH mutation and 1p/19q status of the tumour. (Source: European Journal of Cancer)
Source: European Journal of Cancer - July 26, 2020 Category: Cancer & Oncology Authors: Enrico Franceschi, Alicia Tosoni, Stefania Bartolini, Santino Minichillo, Antonella Mura, Sofia Asioli, Daniela Bartolini, Marina Gardiman, Marco Gessi, Claudio Ghimenton, Felice Giangaspero, Giovanni Lanza, Gianluca Marucci, Mariangela Novello, Enrico M. Tags: Original Research Source Type: research

Erratum to ‘Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database’ [European Journal of Cancer, Volume 125 (January 2020) Pages 153–163]
The publisher regrets that the following corrections were missed during the publication of this article. (Source: European Journal of Cancer)
Source: European Journal of Cancer - July 25, 2020 Category: Cancer & Oncology Authors: Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, Sylvestre Le Moulec, Umberto Basso, Alison Birtle, Alastair Thomson, Michael Krainer, Aline Guillot, Ugo De Giorgi, Ali Hasbini, Gedske Daugaard, Amit Bahl, Simon Chowdhury, Orazio Caffo, Phili Tags: Erratum Source Type: research

A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy
These data suggest that there is a benefit to front-line pazopanib in patients with STS who are not candidates for cytotoxic chemotherapy. (Source: European Journal of Cancer)
Source: European Journal of Cancer - July 23, 2020 Category: Cancer & Oncology Authors: Angela C. Hirbe, Vanessa Eulo, Chang I. Moon, Jingqin Luo, Stephanie Myles, Mahesh Seetharam, Jacqui Toeniskoetter, Tammy Kershner, Sasha Haarberg, Mark Agulnik, Varun Monga, Mohammad Milhem, Amanda Parkes, Steven Robinson, Scott Okuno, Steven Attia, Bria Tags: Clinical Trial Source Type: research

Patients with sarcomatoid renal cell carcinoma – re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors
Sarcomatoid renal cell carcinoma (sRCC) represents a rare form of renal cell carcinoma marked by an aggressive biology, poor prognosis and little benefit from anti-angiogenic targeted therapy. More promising results come from the recent therapeutic strategy based on immune checkpoint inhibitor (ICI) combinations. (Source: European Journal of Cancer)
Source: European Journal of Cancer - July 23, 2020 Category: Cancer & Oncology Authors: Roberto Iacovelli, Chiara Ciccarese, Emilio Bria, Sergio Bracarda, Camillo Porta, Giuseppe Procopio, Giampaolo Tortora Tags: Original Research Source Type: research

Relapsing intracranial germ cell tumours warrant retreatment
The optimal therapeutic strategy for relapsing intracranial germ cell tumours (IGCTs) has not been clearly established. (Source: European Journal of Cancer)
Source: European Journal of Cancer - July 23, 2020 Category: Cancer & Oncology Authors: Laetitia Callec, Audrey Lardy-Cleaud, Lea Guerrini-Rousseau, Claire Alapetite, Laure Vignon, Pascal Chastagner, Didier Frappaz, Cecile Faure-Conter Tags: Original Research Source Type: research

Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials
The use of overall survival (OS) as the gold standard primary end-point (PEP) in metastatic oncologic randomised controlled trials (RCTs) has declined in favour of progression-free survival (PFS) without a complete understanding of the degree to which PFS reliably predicts for OS. (Source: European Journal of Cancer)
Source: European Journal of Cancer - July 20, 2020 Category: Cancer & Oncology Authors: Dario Pasalic, Gwendolyn J. McGinnis, C. David Fuller, Aaron J. Grossberg, Vivek Verma, Walker Mainwaring, Austin B. Miller, Timothy A. Lin, Amit Jethanandani, Andres F. Espinoza, Markus Diefenhardt, Prajnan Das, Vivek Subbiah, Ishwaria M. Subbiah, Reshma Tags: Original Research Source Type: research

Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings
The dynamic effects of immune checkpoint inhibitors (ICIs) are a challenge when designing and analysing data in non-proportional hazards (PH) scenarios. Herein, we present the risk of making type II errors, affecting pharmacotherapeutic development when methods that assume constant effects are applied. (Source: European Journal of Cancer)
Source: European Journal of Cancer - July 19, 2020 Category: Cancer & Oncology Authors: Eduardo Casta ñon, Alvaro Sanchez-Arraez, Felipe Alvarez-Manceñido, Paula Jimenez-Fonseca, Alberto Carmona-Bayonas Tags: Original Research Source Type: research

BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study
An association between BRCA pathogenic variants and an increased endometrial cancer risk, specifically serous-like endometrial cancer, has been postulated but remains unproven, particularly for BRCA2 carriers. Mechanistic evidence is lacking, and any link may be related to tamoxifen exposure or testing bias. Hysterectomy during risk-reducing bilateral salpingo-oophorectomy is, therefore, of uncertain benefit. Data from a large, prospective cohort will be informative. (Source: European Journal of Cancer)
Source: European Journal of Cancer - July 19, 2020 Category: Cancer & Oncology Authors: Sarah J. Kitson, Cemsel Bafligil, Neil A.J. Ryan, Fiona Lalloo, Emma R. Woodward, Richard D. Clayton, Richard J. Edmondson, James Bolton, Emma J. Crosbie, D. Gareth Evans Tags: Original Research Source Type: research